From Yahoo Finance: 2025-06-10 13:03:00

Odyssey Therapeutics has withdrawn its registration for an IPO, likely missing the 2025 biotech stock exchange wave. The company aimed to fund its pipeline, including an ulcerative colitis treatment in Phase II trials. The IPO U-turn may reflect uncertainty in the IPO landscape due to economic fallout from US policies.

Biotech IPOs saw a strong recovery in 2024, raising $8.52bn, up 68.4% from 2023. The rebound was driven by US Federal Reserve interest rate cuts. However, Odyssey is not alone in bailing on IPOs; Telix Pharmaceuticals also withdrew its US public listing in June 2024 due to market conditions.



Read more at Yahoo Finance: Odyssey bails on public listing as US IPO landscape stutters